Guido Lancman

1.2k total citations
44 papers, 693 citations indexed

About

Guido Lancman is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Guido Lancman has authored 44 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 18 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Guido Lancman's work include Multiple Myeloma Research and Treatments (24 papers), CAR-T cell therapy research (9 papers) and Protein Degradation and Inhibitors (7 papers). Guido Lancman is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), CAR-T cell therapy research (9 papers) and Protein Degradation and Inhibitors (7 papers). Guido Lancman collaborates with scholars based in United States, Canada and Poland. Guido Lancman's co-authors include Ajai Chari, Joshua Richter, Sundar Jagannath, Hearn Jay Cho, Samir Parekh, Theodore H. Schwartz, Shambavi Richard, Larysa Sanchez, Deepu Madduri and Ajai Chari and has published in prestigious journals such as Blood, Frontiers in Immunology and Carcinogenesis.

In The Last Decade

Guido Lancman

41 papers receiving 684 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Guido Lancman 336 249 168 146 109 44 693
Valeria Quarona 263 0.8× 378 1.5× 256 1.5× 35 0.2× 76 0.7× 16 1.0k
Marc Coustans 59 0.2× 249 1.0× 78 0.5× 33 0.2× 23 0.2× 10 878
Elie Naddaf 37 0.1× 193 0.8× 215 1.3× 52 0.4× 161 1.5× 64 983
Paul O’Connor 99 0.3× 284 1.1× 139 0.8× 60 0.4× 14 0.1× 22 1.1k
Eva Jüttner 127 0.4× 127 0.5× 156 0.9× 24 0.2× 24 0.2× 23 713
Adam Utley 94 0.3× 97 0.4× 146 0.9× 88 0.6× 15 0.1× 15 545
Bruno Brochet 117 0.3× 105 0.4× 109 0.6× 40 0.3× 7 0.1× 12 872
Gianluca Zaccarello 100 0.3× 240 1.0× 189 1.1× 24 0.2× 41 0.4× 11 683
Guilhem Solé 94 0.3× 26 0.1× 250 1.5× 37 0.3× 94 0.9× 62 731
Jens Gertow 202 0.6× 166 0.7× 61 0.4× 16 0.1× 60 0.6× 29 525

Countries citing papers authored by Guido Lancman

Since Specialization
Citations

This map shows the geographic impact of Guido Lancman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Lancman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Lancman more than expected).

Fields of papers citing papers by Guido Lancman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guido Lancman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Lancman. The network helps show where Guido Lancman may publish in the future.

Co-authorship network of co-authors of Guido Lancman

This figure shows the co-authorship network connecting the top 25 collaborators of Guido Lancman. A scholar is included among the top collaborators of Guido Lancman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guido Lancman. Guido Lancman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Devasia, Anup J., Esther Masih‐Khan, Jing Yang, et al.. (2024). Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin. Blood. 144(Supplement 1). 3787–3787. 1 indexed citations
2.
Lancman, Guido, Kevin Song, Darrell White, et al.. (2024). Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement. Frontiers in Oncology. 14. 1446995–1446995. 2 indexed citations
3.
Visram, Alissa, Kelvin Chan, Hsien Seow, et al.. (2024). Comparing the clinical trial efficacy <i>versus</i> real-world effectiveness of treatments for multiple myeloma: a population-based study. Haematologica. 110(1). 228–233.
4.
Masih‐Khan, Esther, Eshetu G. Atenafu, Sita Bhella, et al.. (2024). Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies. Blood. 144(Supplement 1). 1956–1956. 1 indexed citations
5.
Devasia, Anup J., Ajai Chari, & Guido Lancman. (2024). Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer Journal. 14(1). 158–158. 20 indexed citations
6.
Devasia, Anup J., Guido Lancman, & Alexander K. Stewart. (2024). Management of Newly Diagnosed Multiple Myeloma Today, and in the Future. Hematology/Oncology Clinics of North America. 38(2). 441–459. 2 indexed citations
7.
Lancman, Guido, Lisa Avery, Hearn Jay Cho, et al.. (2023). IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discovery. 4(6). 440–451. 56 indexed citations
8.
Zubizarreta, Nicole, Erin Moshier, Douglas Tremblay, et al.. (2022). Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients. Clinical Lymphoma Myeloma & Leukemia. 22(12). 903–911. 8 indexed citations
9.
Lancman, Guido, Samantha E. Jacobs, John T. Doucette, et al.. (2021). Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(5). e470–e476. 18 indexed citations
10.
Lancman, Guido, et al.. (2021). Impact of rituximab on COVID-19 outcomes. Annals of Hematology. 100(11). 2805–2812. 42 indexed citations
11.
Moshier, Erin, Samantha E. Jacobs, Douglas Tremblay, et al.. (2020). Practicing Antimicrobial Stewardship: De-Escalating Antibiotics in Patients With Acute Myeloid Leukemia and Neutropenic Fever. Open Forum Infectious Diseases. 7(5). ofaa138–ofaa138. 7 indexed citations
12.
Lancman, Guido, Bridget K. Marcellino, Santiago Thibaud, & Kevin Troy. (2020). Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19. Annals of Hematology. 100(3). 833–835. 10 indexed citations
13.
Lancman, Guido, Alexander Coltoff, & Amir Steinberg. (2018). Romiplostim for thrombocytopenia following allogeneic stem cell transplantation. Hematology/Oncology and Stem Cell Therapy. 13(3). 171–174. 4 indexed citations
14.
Lancman, Guido, Suzanne Arinsburg, Jeffrey S. Jhang, et al.. (2018). Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. Frontiers in Immunology. 9. 2616–2616. 44 indexed citations
15.
Lancman, Guido, Andrew M. Brunner, Ronald Hoffman, John Mascarenhas, & Gabriela Hobbs. (2018). Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. Leukemia Research. 70. 49–55. 24 indexed citations
16.
Tremblay, Douglas, et al.. (2017). Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents. Bone Marrow Transplantation. 52(10). 1468–1470. 7 indexed citations
17.
Marcuse, Lara, Guido Lancman, Alexis Demopoulos, & Madeline Fields. (2014). Nonconvulsive status epilepticus in patients with brain tumors. Seizure. 23(7). 542–547. 22 indexed citations
18.
Lancman, Guido, Michael S. Virk, Huibo Shao, et al.. (2012). Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox–Gastaut syndrome: A meta-analysis. Seizure. 22(1). 3–8. 99 indexed citations
19.
Luther, Neal, Elayna Rubens, Nitin K. Sethi, et al.. (2011). The value of intraoperative electrocorticography in surgical decision making for temporal lobe epilepsy with normal MRI. Epilepsia. 52(5). 941–948. 35 indexed citations
20.
Lancman, Guido, et al.. (2011). Predictive value of Spanish neuropsychological testing for laterality in patients with epilepsy. Epilepsy & Behavior. 23(2). 142–145. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valeria Quarona Breakdown of academic impact, for papers by Marc Coustans Breakdown of academic impact, for papers by Elie Naddaf Breakdown of academic impact, for papers by Paul O’Connor Breakdown of academic impact, for papers by Eva Jüttner Breakdown of academic impact, for papers by Adam Utley Breakdown of academic impact, for papers by Bruno Brochet Breakdown of academic impact, for papers by Gianluca Zaccarello Breakdown of academic impact, for papers by Guilhem Solé Breakdown of academic impact, for papers by Jens Gertow
Rankless by CCL
2026